Exact Mass: 496.26069400000006
Exact Mass Matches: 496.26069400000006
Found 500 metabolites which its exact mass value is equals to given mass value 496.26069400000006
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Leukotriene D4
C25H40N2O6S (496.26069400000006)
Leukotriene D4 (LTD4) is a cysteinyl leukotriene. Cysteinyl leukotrienes (CysLTs) are a family of potent inflammatory mediators that appear to contribute to the pathophysiologic features of allergic rhinitis. LTD4 is a pro-inflammatory mediator known to mediate its effects through specific cell-surface receptors belonging to the G-protein-coupled receptor family, namely the high-affinity CysLT1 (cysteinyl leukotriene 1) receptor. LTD4 is present at high levels in many inflammatory conditions, and areas of chronic inflammation have an increased risk for subsequent cancer development. LTD4 is associated with the pathogenesis of several inflammatory disorders, such as asthma and inflammatory bowel disease. Exposure to LTD4 increases survival and proliferation in intestinal epithelial cells. CysLT1 regulator is up-regulated in colon cancer tissue and LTD4 signalling facilitates the survival of cancer cells. LTD4 could reduce apoptosis in non-transformed epithelial cells. LTD4 causes up-regulation of beta-catenin through the CysLT1 receptor, PI3K (phosphoinositide 3-kinase), and GSK-3β (glycogen synthase kinase 3β). LTD4 induces beta-catenin translocation to the nucleus and activation of TCF/LEF family of transcription factors. LTD4 causes accumulation of free beta-catenin in non-transformed intestinal epithelial cells through the CysLT1 receptor, and this accumulation is dependent upon the activation of PI3K as well as GSK-3β inactivation (PMID: 16042577, 12607939). Leukotrienes are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent and are able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis through receptor-mediated G-protein linked signaling pathways. Leukotriene D4 (LTD4) is a cysteinyl leukotriene a family of potent inflammatory mediators. LTD4 is a pro-inflammatory mediator known to mediate its effects through specific cell-surface receptors belonging to the G-protein-coupled receptor family, namely the high-affinity CysLT1 (cysteinyl leukotriene 1) receptor. LTD4 is present at high levels in many inflammatory conditions, and areas of chronic inflammation have an increased risk for subsequent cancer development; LTD4 is associated with the pathogenesis of several inflammatory disorders, such as asthma and inflammatory bowel disease. Exposure to LTD4 increases survival and proliferation in intestinal epithelial cells. CysLT1 regulator is up-regulated in colon cancer tissue and LTD4 signalling facilitates the survival of cancer cells. LTD4 could reduce apoptosis in non-transformed epithelial cells. LTD4 causes up-regulation of b-catenin through the CysLT1 receptor, PI3K (phosphoinositide 3-kinase) and GSK-3b (glycogen synthase kinase 3b). LTD4 induces b-catenin translocation to the nucleus and activation of TCF/LEF family of transcription factors. LTD4 causes accumulation of free b-catenin in non-transformed intestinal epithelial cells through the CysLT1 receptor, and this accumulation is dependent upon the activation of PI3K as well as GSK-3b inactivation. (PMID: 16042577, 12607939)
Fexaramine
G-418
C20H40N4O10 (496.27443000000005)
D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D005839 - Gentamicins
APGPR Enterostatin
Enterostatin APGPR (Ala-Pro-Gly-Pro-Arg) is a pentapeptide released from procolipase during fat digestion. In addition to the pancreas, enterostatin-immunoreactive cells are also present in the antrum and proximal small intestine. Enterostatin selectively reduces fat intake, decreases insulin secretion, and also increases energy expenditure by activating brown adipose tissue during high-fat feeding. Enterostatins are pentapeptides derived from the NH2-terminus of procolipase after tryptic cleavage and belong to the family of gut-brain peptides. Enterostatin is generated by the action of trypsin on procolipase in the intestinal lumen. Its structure is highly conserved in evolution, with an amino acid sequence of XPXPR. Three enterostatin sequences, Val-Pro-Asp-Pro-Arg (VPDPR), Val-Pro-Gly-Pro-Arg (VPGPR), and Ala-Pro-Gly-Pro-Arg (APGPR), have been studied extensively and shown to be almost equally effective in their ability to decrease dietary fat preference. Enterostatins are selective inhibitors of appetite, particularly of fat intake. Hyperenterostatinemia in obesity is probably secondary to enterostatin resistance; therefore, the regulatory system is producing more enterostatin to counteract the resistance. This is very similar to hyperinsulinemia and hyperleptinemia in obesity. The diminution in the meal-induced secretion of enterostatin in obesity suggests a delay in the appearance of satiety, leading to increased caloric intake. In rats enterostatin decreases body weight by decreasing fat-calorie intake and increasing the sympathetic firing rate of the nerves in interscapular brown adipose tissue. Enterostatin levels are elevated in the plasma of obese women, and enterostatin secretion is diminished after satiety. Oral administration of enterostatin, however, has no effect on food intake, energy expenditure, or body weight in subjects with a preference for a high-fat diet experiencing a negative energy and fat balance, and the physiology of enterostatin in humans remains to be defined. (PMID: 10084574, 9526102, 8886249) [HMDB] Enterostatin APGPR (Ala-Pro-Gly-Pro-Arg) is a pentapeptide released from procolipase during fat digestion. In addition to the pancreas, enterostatin-immunoreactive cells are also present in the antrum and proximal small intestine. Enterostatin selectively reduces fat intake, decreases insulin secretion, and also increases energy expenditure by activating brown adipose tissue during high-fat feeding. Enterostatins are pentapeptides derived from the NH2-terminus of procolipase after tryptic cleavage and belong to the family of gut-brain peptides. Enterostatin is generated by the action of trypsin on procolipase in the intestinal lumen. Its structure is highly conserved in evolution, with an amino acid sequence of XPXPR. Three enterostatin sequences, Val-Pro-Asp-Pro-Arg (VPDPR), Val-Pro-Gly-Pro-Arg (VPGPR), and Ala-Pro-Gly-Pro-Arg (APGPR), have been studied extensively and shown to be almost equally effective in their ability to decrease dietary fat preference. Enterostatins are selective inhibitors of appetite, particularly of fat intake. Hyperenterostatinemia in obesity is probably secondary to enterostatin resistance; therefore, the regulatory system is producing more enterostatin to counteract the resistance. This is very similar to hyperinsulinemia and hyperleptinemia in obesity. The diminution in the meal-induced secretion of enterostatin in obesity suggests a delay in the appearance of satiety, leading to increased caloric intake. In rats enterostatin decreases body weight by decreasing fat-calorie intake and increasing the sympathetic firing rate of the nerves in interscapular brown adipose tissue. Enterostatin levels are elevated in the plasma of obese women, and enterostatin secretion is diminished after satiety. Oral administration of enterostatin, however, has no effect on food intake, energy expenditure, or body weight in subjects with a preference for a high-fat diet experiencing a negative energy and fat balance, and the physiology of enterostatin in humans remains to be defined. (PMID: 10084574, 9526102, 8886249). Enterostatin, human, mouse, rat is a pentapeptide that reduces fat intake. Enterostatin, human, mouse, rat is a pentapeptide that reduces fat intake.
geneticin
C20H40N4O10 (496.27443000000005)
D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D005839 - Gentamicins
6-[2-Amino-3-(carboxymethylamino)-3-oxopropyl]sulfanyl-5-hydroxyicosa-7,9,11,14-tetraenoic acid
C25H40N2O6S (496.26069400000006)
Fexaramine
Prochaetoglobosin II
A cytochalasan alkaloid found in Chaetomium globosum and Chaetomium subaffine.
O-beta-D-Glucopyranoside-(ent-11alpha,16alpha)-11-Hydroxy-15-oxo-kauranoic acid
6alpha-19-[3-(4-Hydroxyphenyl)propanoyl] ester:6,19-Dihydroxy-3-oxo-5(10),13-halimadien-15,16-olide
12-O-beta-D-glucopyranosyl-3,11,16-trihydroxyabieta-8,11,13-triene
18-O-beta-D-glucopyranosyl,19-hydroxy-5alpha,10beta-neo-cleroda-3,13(14)-dien-16,15-butenolide|soulidioside
(-)-19-beta-D-glucopyranosyl 6,7-dihydroxy-kaurenoate
(1S*,2S*,3S*,4R*,4aR*,5R*,6R*,9R*,10S*,12R*,12aS*)-tetradecahydro-1,6,10-trimethyl-4-(1-methylethyl)-5,12:6,9-diepoxybenzocyclododecene-1,2,3,9-tetrol 1,2,3-triacetate|massileunicellin C
1-O-decanoyl-6-O-D-beta-glucopyranosyl-beta-D-glucopyranose|6-O-(beta-D-glucopyranosyl)-1-O-decanoyl-beta-D-glucopyranose|nonioside R
C22H40O12 (496.25196400000004)
15-O-acetyl-3-O-benzoylcharaciol-5beta,6beta-oxide
21,25,26,27-tetranorapoeupha-6alpha-methoxy-7alpha-acetoxy-2,14,20(22)-trien-1,12,16,23-tetraone|21,25,26,27-tetranorapotirucalla-6alpha-methoxy-7alpha-acetoxy-2,14,20(22)-trien-1,12,16,23-tetraone|meliatetraone
13S-hydroxy-labda-7,14-dien-6-oxo-19-oic acid beta-D-glucopyranoside|cathargyroside A
beta-D-glucopyranosyl (13S)-13-hydroxy-7-oxo-labda-8,14-diene-18-oate
15-hydroxy-labda-7,13E-dien-6-oxo-19-oic acid beta-D-glucopyranoside|cathargyroside B
macropodumine J|methyl rel-(3R,6R,10aS,11S,12aS)-5-(acetyloxy)-5a-[(acetyloxy)methyl]-12b-cyano-2,3,3a,5,5a,6,7,8,9,10,10a,11,12,12b-tetradecahydro-3-methyl-4H-1,6-methanocyclopenta[1,8]azuleno[4,3a-g]indole-11-carboxylate
(16S)-dihydrohyalic acid beta-glucopyranosyl ester
Val His Ile Glu
Andropanoside
Andropanoside is a natural product found in Andrographis paniculata with data available.
[(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methyl 8-methylnonanoate
C22H40O12 (496.25196400000004)
C26H40O9_2,4a,6-Trihydroxy-8-isopropyl-1,1-dimethyl-2,3,4,4a,5,10,11,11a-octahydro-1H-dibenzo[a,d][7]annulen-7-yl beta-D-glucopyranoside
LTD4-[d5]
C25H40N2O6S (496.26069400000006)
CONFIDENCE standard compound; NATIVE_RUN_ID STD_neg_MSMS_1min0222.mzML; PROCESSING averaging of repeated ion fragments at 30.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID STD_neg_MSMS_1min0222.mzML; PROCESSING averaging of repeated ion fragments at 20.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID STD_neg_MSMS_1min0222.mzML; PROCESSING averaging of repeated ion fragments at 10.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0000153.mzML; PROCESSING averaging of repeated ion fragments at 30.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0000153.mzML; PROCESSING averaging of repeated ion fragments at 20.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0000153.mzML; PROCESSING averaging of repeated ion fragments at 10.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0000153.mzML; PROCESSING averaging of repeated ion fragments at 40.0 NCE within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0000153.mzML; PROCESSING averaging of repeated ion fragments at 30.0 NCE within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0000153.mzML; PROCESSING averaging of repeated ion fragments at 20.0 NCE within 5 ppm window [MS, MS:1000575, mean of spectra, ]
[(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methyl 8-methylnonanoate [IIN-based on: CCMSLIB00000846747]
C22H40O12 (496.25196400000004)
[(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methyl 8-methylnonanoate [IIN-based: Match]
C22H40O12 (496.25196400000004)
Geneticin
C20H40N4O10 (496.27443000000005)
An aminoglycoside antibiotic produced by Micromonospora rhodorangea. It blocks polypeptide synthesis by inhibiting the elongation step in both prokaryotic and eukaryotic cells.
Ala Phe Phe Ile
Ala Phe Phe Leu
Ala Phe Ile Phe
Ala Phe Leu Phe
Ala His Asn Arg
Ala His Arg Asn
Ala Ile Phe Phe
Ala Leu Phe Phe
Ala Asn His Arg
Ala Asn Arg His
Ala Arg His Asn
Ala Arg Asn His
Asp His Ile Ile
Asp His Ile Leu
Asp His Leu Ile
Asp His Leu Leu
Asp Ile His Ile
Asp Ile His Leu
Asp Ile Ile His
Asp Ile Leu His
Asp Leu His Ile
Asp Leu His Leu
Asp Leu Ile His
Asp Leu Leu His
Glu His Ile Val
Glu His Leu Val
Glu His Val Ile
Glu His Val Leu
Glu Ile His Val
Glu Ile Val His
Glu Leu His Val
Glu Leu Val His
Glu Val His Ile
Glu Val His Leu
Glu Val Ile His
Glu Val Leu His
Phe Ala Phe Ile
Phe Ala Phe Leu
Phe Ala Ile Phe
Phe Ala Leu Phe
Phe Phe Ala Ile
Phe Phe Ala Leu
Phe Phe Ile Ala
Phe Phe Leu Ala
Phe His Pro Pro
Phe Ile Ala Phe
Phe Ile Phe Ala
Phe Leu Ala Phe
Phe Leu Phe Ala
Phe Pro His Pro
Phe Pro Pro His
Gly His Gln Arg
Gly His Arg Gln
Gly Gln His Arg
Gly Gln Arg His
Gly Arg His Gln
Gly Arg Gln His
His Ala Asn Arg
His Ala Arg Asn
His Asp Ile Ile
His Asp Ile Leu
His Asp Leu Ile
His Asp Leu Leu
His Glu Ile Val
His Glu Leu Val
His Glu Val Ile
His Glu Val Leu
His Phe Pro Pro
His Gly Gln Arg
His Gly Arg Gln
His Ile Asp Ile
His Ile Asp Leu
His Ile Glu Val
His Ile Ile Asp
His Ile Leu Asp
His Ile Met Pro
C22H36N6O5S (496.24677660000003)
His Ile Pro Met
C22H36N6O5S (496.24677660000003)
His Ile Val Glu
His Lys Asn Val
His Lys Val Asn
His Leu Asp Ile
His Leu Asp Leu
His Leu Glu Val
His Leu Ile Asp
His Leu Leu Asp
His Leu Met Pro
C22H36N6O5S (496.24677660000003)
His Leu Pro Met
C22H36N6O5S (496.24677660000003)
His Leu Val Glu
His Met Ile Pro
C22H36N6O5S (496.24677660000003)
His Met Leu Pro
C22H36N6O5S (496.24677660000003)
His Met Pro Ile
C22H36N6O5S (496.24677660000003)
His Met Pro Leu
C22H36N6O5S (496.24677660000003)
His Asn Ala Arg
His Asn Lys Val
His Asn Arg Ala
His Asn Val Lys
His Pro Phe Pro
His Pro Ile Met
C22H36N6O5S (496.24677660000003)
His Pro Leu Met
C22H36N6O5S (496.24677660000003)
His Pro Met Ile
C22H36N6O5S (496.24677660000003)
His Pro Met Leu
C22H36N6O5S (496.24677660000003)
His Pro Pro Phe
His Gln Gly Arg
His Gln Arg Gly
His Arg Ala Asn
His Arg Gly Gln
His Arg Asn Ala
His Arg Gln Gly
His Val Glu Ile
His Val Glu Leu
His Val Ile Glu
His Val Lys Asn
His Val Leu Glu
His Val Asn Lys
Ile Ala Phe Phe
Ile Asp His Ile
Ile Asp His Leu
Ile Asp Ile His
Ile Asp Leu His
Ile Glu His Val
Ile Glu Val His
Ile Phe Ala Phe
Ile Phe Phe Ala
Ile His Asp Ile
Ile His Asp Leu
Ile His Glu Val
Ile His Ile Asp
Ile His Leu Asp
Ile His Met Pro
C22H36N6O5S (496.24677660000003)
Ile His Pro Met
C22H36N6O5S (496.24677660000003)
Ile His Val Glu
Ile Ile Asp His
Ile Ile His Asp
Ile Leu Asp His
Ile Leu His Asp
Ile Met His Pro
C22H36N6O5S (496.24677660000003)
Ile Met Pro His
C22H36N6O5S (496.24677660000003)
Ile Pro His Met
C22H36N6O5S (496.24677660000003)
Ile Pro Met His
C22H36N6O5S (496.24677660000003)
Ile Thr Thr Tyr
Ile Thr Tyr Thr
Ile Val Glu His
Ile Val His Glu
Ile Tyr Thr Thr
Lys His Asn Val
Lys His Val Asn
Lys Asn His Val
Lys Asn Val His
Lys Val His Asn
Lys Val Asn His
Leu Ala Phe Phe
Leu Asp His Ile
Leu Asp His Leu
Leu Asp Ile His
Leu Asp Leu His
Leu Glu His Val
Leu Glu Val His
Leu Phe Ala Phe
Leu Phe Phe Ala
Leu His Asp Ile
Leu His Asp Leu
Leu His Glu Val
Leu His Ile Asp
Leu His Leu Asp
Leu His Met Pro
C22H36N6O5S (496.24677660000003)
Leu His Pro Met
C22H36N6O5S (496.24677660000003)
Leu His Val Glu
Leu Ile Asp His
Leu Ile His Asp
Leu Leu Asp His
Leu Leu His Asp
Leu Met His Pro
C22H36N6O5S (496.24677660000003)
Leu Met Pro His
C22H36N6O5S (496.24677660000003)
Leu Pro His Met
C22H36N6O5S (496.24677660000003)
Leu Pro Met His
C22H36N6O5S (496.24677660000003)
Leu Thr Thr Tyr
Leu Thr Tyr Thr
Leu Val Glu His
Leu Val His Glu
Leu Tyr Thr Thr
Met His Ile Pro
C22H36N6O5S (496.24677660000003)
Met His Leu Pro
C22H36N6O5S (496.24677660000003)
Met His Pro Ile
C22H36N6O5S (496.24677660000003)
Met His Pro Leu
C22H36N6O5S (496.24677660000003)
Met Ile His Pro
C22H36N6O5S (496.24677660000003)
Met Ile Pro His
C22H36N6O5S (496.24677660000003)
Met Leu His Pro
C22H36N6O5S (496.24677660000003)
Met Leu Pro His
C22H36N6O5S (496.24677660000003)
Met Pro His Ile
C22H36N6O5S (496.24677660000003)
Met Pro His Leu
C22H36N6O5S (496.24677660000003)
Met Pro Ile His
C22H36N6O5S (496.24677660000003)
Met Pro Leu His
C22H36N6O5S (496.24677660000003)
Asn Ala His Arg
Asn Ala Arg His
Asn His Ala Arg
Asn His Lys Val
Asn His Arg Ala
Asn His Val Lys
Asn Lys His Val
Asn Lys Val His
Asn Gln Val His
C20H32N8O7 (496.23938419999996)
Asn Arg Ala His
Asn Arg His Ala
Asn Val His Lys
Asn Val His Gln
C20H32N8O7 (496.23938419999996)
Asn Val Lys His
Asn Val Gln His
C20H32N8O7 (496.23938419999996)
Pro Phe His Pro
Pro Phe Pro His
Pro His Phe Pro
Pro His Ile Met
C22H36N6O5S (496.24677660000003)
Pro His Leu Met
C22H36N6O5S (496.24677660000003)
Pro His Met Ile
C22H36N6O5S (496.24677660000003)
Pro His Met Leu
C22H36N6O5S (496.24677660000003)
Pro His Pro Phe
Pro Ile His Met
C22H36N6O5S (496.24677660000003)
Pro Ile Met His
C22H36N6O5S (496.24677660000003)
Pro Leu His Met
C22H36N6O5S (496.24677660000003)
Pro Leu Met His
C22H36N6O5S (496.24677660000003)
Pro Met His Ile
C22H36N6O5S (496.24677660000003)
Pro Met His Leu
C22H36N6O5S (496.24677660000003)
Pro Met Ile His
C22H36N6O5S (496.24677660000003)
Pro Met Leu His
C22H36N6O5S (496.24677660000003)
Pro Pro Phe His
Pro Pro His Phe
Pro Pro Gln Arg
Pro Pro Arg Gln
Pro Gln Pro Arg
Pro Gln Arg Pro
Pro Arg Pro Gln
Pro Arg Gln Pro
Gln Gly His Arg
Gln Gly Arg His
Gln His Gly Arg
Gln His Arg Gly
Gln Pro Pro Arg
Gln Pro Arg Pro
Gln Arg Gly His
Gln Arg His Gly
Gln Arg Pro Pro
Arg Ala His Asn
Arg Ala Asn His
Arg Gly His Gln
Arg Gly Gln His
Arg His Ala Asn
Arg His Gly Gln
Arg His Asn Ala
Arg His Gln Gly
Arg Asn Ala His
Arg Asn His Ala
Arg Pro Pro Gln
Arg Pro Gln Pro
Arg Gln Gly His
Arg Gln His Gly
Arg Gln Pro Pro
Thr Ile Thr Tyr
Thr Ile Tyr Thr
Thr Leu Thr Tyr
Thr Leu Tyr Thr
Thr Thr Ile Tyr
Thr Thr Leu Tyr
Thr Thr Tyr Ile
Thr Thr Tyr Leu
Thr Tyr Ile Thr
Thr Tyr Leu Thr
Thr Tyr Thr Ile
Thr Tyr Thr Leu
Val Glu His Ile
Val Glu His Leu
Val Glu Ile His
Val Glu Leu His
Val His Glu Ile
Val His Glu Leu
Val His Lys Asn
Val His Leu Glu
Val His Asn Lys
Val Ile Glu His
Val Ile His Glu
Val Lys His Asn
Val Lys Asn His
Val Leu Glu His
Val Leu His Glu
Val Asn His Lys
Val Asn Lys His
Tyr Ile Thr Thr
Tyr Leu Thr Thr
Tyr Thr Ile Thr
Tyr Thr Leu Thr
Tyr Thr Thr Ile
Tyr Thr Thr Leu
11-trans-LTD4
C25H40N2O6S (496.26069400000006)
14,15-LTD4
C25H40N2O6S (496.26069400000006)
APGPR
Enterostatin, human, mouse, rat is a pentapeptide that reduces fat intake. Enterostatin, human, mouse, rat is a pentapeptide that reduces fat intake.
Leukotriene D4
C25H40N2O6S (496.26069400000006)
A leukotriene that is (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid substituted by a hydroxy group at position 5 (5S) and a L-cysteinylglycinyl group at position 6 (6R).
1,1,3,3,3,3-hexamethylindotricarbocyanine tetrafluoroborate
(4R,15R)-11β,15-Dihydroxykaur-16-en-18-oic acid [β-D-glucopyranosyl] ester
4-Methyl-N-(3-Morpholin-4-Ylphenyl)-3-(3-Piperidin-4-Yl-1,2-Benzisoxazol-6-Yl)benzamide
C30H32N4O3 (496.24742819999994)
2,2,3,3-tetramethyl-N-[4-[4-[(2,2,3,3-tetramethylcyclopropanecarbonyl)amino]phenyl]sulfonylphenyl]cyclopropane-1-carboxamide
C28H36N2O4S (496.23956560000005)
(1R,2S,3S,4R,6S)-4,6-diamino-3-[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyloxy]-2-hydroxycyclohexyl 2-amino-2,7-dideoxy-D-glycero-alpha-D-gluco-heptopyranoside
C20H40N4O10 (496.27443000000005)
D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D005839 - Gentamicins
(2R,3S,4S,5R,6R)-2-(1-aminoethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-3-[(2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-(methylamino)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol
C20H40N4O10 (496.27443000000005)
2-Palmitoyl-sn-glycero-3-phosphoserine
C22H43NO9P- (496.2675298000001)
9-[(E)-4-[(6S)-2-[(1S,2S,3S)-1,3-dihydroxy-2-methylbutyl]-7-oxo-3,4-dihydro-2H-furo[3,2-c]pyran-6-yl]-3-methylbut-2-enoyl]oxynonanoic acid
9-[(E)-4-[(6S)-4-hydroxy-3-[[3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]-5-oxo-2H-pyran-6-yl]-3-methylbut-2-enoyl]oxynonanoic acid
Methyl (Z)-3-[3-[cyclohexanecarbonyl-[[4-[4-(dimethylamino)phenyl]phenyl]methyl]amino]phenyl]prop-2-enoate
6-[2-Amino-3-(carboxymethylamino)-3-oxopropyl]sulfanyl-5-hydroxyicosa-7,9,11,14-tetraenoic acid
C25H40N2O6S (496.26069400000006)
1-Palmitoyl-sn-glycero-3-phosphoserine(1-)
C22H43NO9P- (496.2675298000001)
(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[(1,4,13-trihydroxy-12,12-dimethyl-6-propan-2-yl-5-tricyclo[9.4.0.03,8]pentadeca-3,5,7-trienyl)oxy]oxane-3,4,5-triol
N-[[(8S,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N,1-dimethyl-6-indolecarboxamide
2-[(3alpha-Hydroxy-7,24-dioxo-5beta-cholan-24-yl)amino]ethane-1-sulfonate
C26H42NO6S- (496.2732692000001)
N-[[(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N,1-dimethyl-6-indolecarboxamide
N-[[(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N,1-dimethyl-6-indolecarboxamide
N-[[(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N,1-dimethyl-6-indolecarboxamide
N-[[(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N,1-dimethyl-6-indolecarboxamide
N-[[(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N,1-dimethyl-6-indolecarboxamide
N-[[(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N,1-dimethyl-6-indolecarboxamide
N-[[(8S,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N,1-dimethyl-6-indolecarboxamide
N-[[(8S,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N,1-dimethyl-6-indolecarboxamide
N-[[(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N,1-dimethyl-6-indolecarboxamide
3-(3-fluorophenyl)-1-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea
(8R,9R,10R)-10-(hydroxymethyl)-N-(4-methoxyphenyl)-9-[4-[2-(2-pyridinyl)ethynyl]phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
C30H32N4O3 (496.24742819999994)
N-[[(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N,1-dimethyl-6-indolecarboxamide
[(2R,3S,4S,5R,6S)-3,4,5-Trihydroxy-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methyl 8-methylnonanoate
C22H40O12 (496.25196400000004)
N-[[(8S,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N,1-dimethyl-6-indolecarboxamide
[(8S,9R,10S)-6-(3-methoxyphenyl)sulfonyl-9-[4-(4-methylpent-1-ynyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
C28H36N2O4S (496.23956560000005)
3-(3-fluorophenyl)-1-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea
(1S,9R,10R,11R)-12-(cyclopropylmethyl)-10-(hydroxymethyl)-6-oxo-5-[(E)-2-phenylethenyl]-N-(pyridin-2-ylmethyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
C30H32N4O3 (496.24742819999994)
(2R,3R,3aS,9bS)-7-(1-cyclopentenyl)-N-[3-(dimethylamino)propyl]-3-(hydroxymethyl)-6-oxo-1-(3,3,3-trifluoropropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
C25H35F3N4O3 (496.26611160000004)
[(8R,9S,10R)-6-(3-methoxyphenyl)sulfonyl-9-[4-(4-methylpent-1-ynyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
C28H36N2O4S (496.23956560000005)
(8R,9R,10S)-9-[4-(3-cyanophenyl)phenyl]-10-(hydroxymethyl)-N-(2-methoxyphenyl)-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
C30H32N4O3 (496.24742819999994)
(8S,9R,10R)-9-[4-(3-cyanophenyl)phenyl]-10-(hydroxymethyl)-N-(2-methoxyphenyl)-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
C30H32N4O3 (496.24742819999994)
(8R,9R,10R)-9-[4-(3-cyanophenyl)phenyl]-10-(hydroxymethyl)-N-(2-methoxyphenyl)-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
C30H32N4O3 (496.24742819999994)
[(E)-[(1R,4aR,4bS,8aS,10aS)-1-[2-[(2S)-2-methoxy-5-oxo-2H-furan-4-yl]ethyl]-4b,8,8,10a-tetramethyl-1,3,4,4a,5,6,7,8a,9,10-decahydrophenanthren-2-ylidene]methyl] hydrogen sulfate
C26H40O7S (496.24946100000005)
[(E)-[(1R,4aR,4bS,8aS,10aS)-1-[2-[(2R)-2-methoxy-5-oxo-2H-furan-4-yl]ethyl]-4b,8,8,10a-tetramethyl-1,3,4,4a,5,6,7,8a,9,10-decahydrophenanthren-2-ylidene]methyl] hydrogen sulfate
C26H40O7S (496.24946100000005)
N-[[(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N,1-dimethyl-6-indolecarboxamide
N-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(pyridine-2-carbonyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(5R,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-[oxo(3-pyridinyl)methyl]-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-[oxo(3-pyridinyl)methyl]-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-[oxo(3-pyridinyl)methyl]-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
(2S,3S,3aR,9bR)-7-[4-[dimethylamino(oxo)methyl]phenyl]-3-(hydroxymethyl)-N-(2-methoxyethyl)-6-oxo-1-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
N-[[(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N,1-dimethyl-6-indolecarboxamide
N-[[(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N,1-dimethyl-6-indolecarboxamide
N-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(pyridine-2-carbonyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(4S,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-[oxo(2-pyridinyl)methyl]-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(pyridine-3-carbonyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
(2S,3S,3aR,9bR)-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-2-(piperidine-1-carbonyl)-N-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1-carboxamide
(2R,3R,3aS,9bS)-N-[3-(dimethylamino)propyl]-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-1-propanoyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(2R,3R,3aS,9bS)-7-[4-(dimethylcarbamoyl)phenyl]-3-(hydroxymethyl)-N-(2-methoxyethyl)-6-oxo-1-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
1-[[(2S,3R)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-3-(3-fluorophenyl)-1-methylurea
1-[[(2S,3S)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-3-(3-fluorophenyl)-1-methylurea
1-[[(2R,3S)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-3-(3-fluorophenyl)-1-methylurea
1-[[(2R,3S)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-3-(3-fluorophenyl)-1-methylurea
N-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-[oxo(2-pyridinyl)methyl]-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-[oxo(2-pyridinyl)methyl]-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(4R,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-[oxo(pyridin-4-yl)methyl]-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-[oxo(pyridin-4-yl)methyl]-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
1-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-phenylurea
1-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-phenylurea
(2R,3R,3aS,9bS)-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-2-[oxo(1-piperidinyl)methyl]-N-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1-carboxamide
[(8S,9S,10R)-6-(3-methoxyphenyl)sulfonyl-9-[4-(4-methylpent-1-ynyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
C28H36N2O4S (496.23956560000005)
(8R,9S,10R)-9-[4-(3-cyanophenyl)phenyl]-10-(hydroxymethyl)-N-(2-methoxyphenyl)-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
C30H32N4O3 (496.24742819999994)
(8S,9R,10S)-9-[4-(3-cyanophenyl)phenyl]-10-(hydroxymethyl)-N-(2-methoxyphenyl)-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
C30H32N4O3 (496.24742819999994)
(8S,9S,10R)-9-[4-(3-cyanophenyl)phenyl]-10-(hydroxymethyl)-N-(2-methoxyphenyl)-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
C30H32N4O3 (496.24742819999994)
N-[[(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N,1-dimethyl-6-indolecarboxamide
1-[[(2R,3R)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-3-(3-fluorophenyl)-1-methylurea
3-(3-fluorophenyl)-1-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea
3-(3-fluorophenyl)-1-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea
3-(3-fluorophenyl)-1-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea
3-(3-fluorophenyl)-1-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea
1-[[(2R,3R)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-3-(3-fluorophenyl)-1-methylurea
1-[[(2S,3S)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-3-(3-fluorophenyl)-1-methylurea
1-[[(2S,3R)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-3-(3-fluorophenyl)-1-methylurea
3-(3-fluorophenyl)-1-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea
3-(3-fluorophenyl)-1-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea
N-[(4R,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-[oxo(2-pyridinyl)methyl]-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-[oxo(2-pyridinyl)methyl]-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(4R,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-[oxo(2-pyridinyl)methyl]-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-[oxo(3-pyridinyl)methyl]-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-[oxo(3-pyridinyl)methyl]-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(4R,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-[oxo(pyridin-4-yl)methyl]-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(4S,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-[oxo(pyridin-4-yl)methyl]-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-[oxo(pyridin-4-yl)methyl]-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-[oxo(pyridin-4-yl)methyl]-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-[oxo(pyridin-4-yl)methyl]-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-[oxo(pyridin-4-yl)methyl]-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
1-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-phenylurea
1-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-phenylurea
1-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-phenylurea
1-[(5R,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-phenylurea
1-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-phenylurea
1-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-phenylurea
2-[(3R,6aS,8S,10aS)-3-hydroxy-1-[(4-phenoxyphenyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-morpholinyl)ethanone
(2S,3S,3aR,9bR)-7-(1-cyclopentenyl)-N-[3-(dimethylamino)propyl]-3-(hydroxymethyl)-6-oxo-1-(3,3,3-trifluoropropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
C25H35F3N4O3 (496.26611160000004)
(2S,3S,3aR,9bR)-N-[3-(dimethylamino)propyl]-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-1-(1-oxopropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
[(8S,9S,10S)-6-(3-methoxyphenyl)sulfonyl-9-[4-(4-methylpent-1-ynyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
C28H36N2O4S (496.23956560000005)
[(8R,9R,10R)-6-(3-methoxyphenyl)sulfonyl-9-[4-(4-methylpent-1-ynyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
C28H36N2O4S (496.23956560000005)
[(8S,9R,10R)-6-(3-methoxyphenyl)sulfonyl-9-[4-(4-methylpent-1-ynyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
C28H36N2O4S (496.23956560000005)
[(8R,9R,10S)-6-(3-methoxyphenyl)sulfonyl-9-[4-(4-methylpent-1-ynyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
C28H36N2O4S (496.23956560000005)
(8S,9S,10S)-9-[4-(3-cyanophenyl)phenyl]-10-(hydroxymethyl)-N-(2-methoxyphenyl)-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
C30H32N4O3 (496.24742819999994)
(8R,9S,10S)-9-[4-(3-cyanophenyl)phenyl]-10-(hydroxymethyl)-N-(2-methoxyphenyl)-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
C30H32N4O3 (496.24742819999994)
(1R,9S,10S,11S)-N-[3-(dimethylamino)propyl]-12-(2-fluorobenzoyl)-10-(hydroxymethyl)-6-oxo-5-[(E)-prop-1-enyl]-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(1S,9R,10R,11R)-N-[3-(dimethylamino)propyl]-12-(2-fluorobenzoyl)-10-(hydroxymethyl)-6-oxo-5-[(E)-prop-1-enyl]-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-propanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (Z)-tridec-9-enoate
[1-[(2-acetyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (Z)-tetradec-9-enoate
[1-acetyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (Z)-tetradec-9-enoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (Z)-tridec-9-enoate
APGPR Enterostatin
Enterostatin, human, mouse, rat is a pentapeptide that reduces fat intake. Enterostatin, human, mouse, rat is a pentapeptide that reduces fat intake.
1-(9Z-heptadecenoyl)-glycero-3-phospho-(1-sn-glycerol)
eoxin D4
C25H40N2O6S (496.26069400000006)
A leukotriene that is the 14R-(S-cysteinylglycyl),15S-hydroxy derivative of (5Z,8Z,10E,12E)-icosa-7,9,11,14-tetraenoic acid.